Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies and cancer: perspectives with opinion and commentary.

Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies and cancer: perspectives with opinion and commentary. Expert Rev Hematol. 2020 Oct 08;: Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the establishment of ESAs as integral in the treatment of anemia. Multiple RCTs and meta-analyses studying the use of ESAs are presented with focus upon their application to clinical practice. A "compendium" is proffered describing the evolution, establishment, and implications of ESA administration initially among those with CKD with rapid subsequent application to the Hematology-Oncology population of patients. Literature search methodologies have included MEDLINE (1985-2020), PubMed (1996-2020), Cochrane Central Trials (1985-2020), EMBASE (2000-2020) and ClinicalTrials.gov (2000-2020). EXPERT OPINION: Upon evaluation of risks a...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research